Jobs
-
The FDA has accepted Boehringer Ingelheim’s New Drug Application for its tiotropium/olodaterol Respimat soft mist inhaler for the treatment of COPD, the company has announced. BI’s Striverdi Respimat olodaterol SMI was approved by the FDA… Read more . . .
-
The United States Pharmacopeial Convention (USP) has announced three recipients of its 2014–2015 Global Fellowship Awards. One of the recipients of the $30,000 fellowship, Ahmed Shalash of Alexandria University in Alexandria, Egypt, is researching carriers… Read more . . .
-
In addition to its 20% acetylcysteine solution products, Fresenius Kabi is now offering 4 ml, 10 ml, and 30 ml vials of acetylcysteine 10% for oral use or inhalation in the US. Acetylcysteine is a… Read more . . .
-
The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 10-3 to approve Boehringer Ingelheim’s Spiriva Respimat tiotropium soft mist inhaler for the treatment of COPD. BI’s first NDA submission for tiotropium Respimat took place in… Read more . . .
-
Skyepharma says that it will begin developing a COPD therapy based on Pulmagen’s ICS “re-sensitization” technology (SKP-2075) by the end of 2014 after acquiring the IP and global rights to the Theocort platform from Pulmagen.… Read more . . .
-
CDMO Formex, LLC has announced that former Azo Pharma VP of Formulation Development John McCarty has joined the company as Scientific Advisor. McCarty will also serve as a member of the company’s Science Advisory Board.… Read more . . .
-
3M Drug Delivery Systems has announced that it has entered into a licensing agreement with Presspart for sales of the 3M Dose by Dose Counter and dose indicator. 3M DDS President and General Manager Cindy… Read more . . .
-
Cambridge Consultants has announced plans to more than triple its US staff to 100+ over the next few years, with a focus on hiring for its medical technology business, especially drug delivery device development. The… Read more . . .
-
Insmed Incorporated is offering 8.9 million shares of common stock at $11.25 per share, with expected net proceeds of $94 million to go toward continued development of Arikayce liposomal amikacin for inhalation. The company recently… Read more . . .
-
Sanofi will pay MannKind $150 million upfront and milestone payments of up to $775 million for an exclusive development and commercialization license for Afrezza insulin inhalation powder, the companies have announced. The companies will split… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK